{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T18:16:24Z","timestamp":1778264184686,"version":"3.51.4"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:p>ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is standard upfront chemotherapy for adults diagnosed with Hodgkin lymphoma (HL), but positron emission tomography (PET)-based response data following ABVD is lacking for pediatrics. Among children who received ABVD for HL, we document interim and end of therapy PET-computed tomography (CT) response by Deauville criteria, and survival outcomes following a response-based reduction in involved field radiotherapy (IFRT). Children 18 years of age or below with HL treated with ABVD between 2006 and 2015 who had interim PET\/CT scans after 2 cycles of chemotherapy were included. Interim and end of therapy PET\/CT scans were retrospectively re-evaluated using Deauville criteria by 3 radiologists. Among 45 children, 32 (71%) met criteria for intermediate risk, 86% achieved rapid early response (RER) and only 4 (9%) received upfront IFRT. Patients achieving RER had superior 5-year event-free survival (EFS) 95%\u00b14% versus 50%\u00b118% (<jats:italic toggle=\"yes\">P<\/jats:italic>\u22640.001) and overall survival (OS) 100% versus 83%\u00b115% (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.025). <jats:italic toggle=\"yes\">P<\/jats:italic>atients with bulk who achieved RER and received no IFRT achieved 5-year EFS of 92%\u00b16% and OS 100%. Low, intermediate, and high risk patients had 5-year EFS of 100%, 94%\u00b14%, and 50%\u00b118% (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.002) and 5-year OS of 100%, 100%, and 75%\u00b115% (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.03). RER following 2 cycles of ABVD is predictive of survival outcomes in children and adolescents with HL and may identify a group who may omit IFRT.<\/jats:p>","DOI":"10.1097\/mph.0000000000001534","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T13:18:34Z","timestamp":1561727914000},"page":"e87-e93","source":"Crossref","is-referenced-by-count":6,"title":["The Utility of PET\/CT in Guiding Radiotherapy Reduction for Children With Hodgkin Lymphoma Treated With ABVD"],"prefix":"10.1097","volume":"42","author":[{"given":"Katrina M.","family":"Ingley","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology\/Bone Marrow Transplantation, British Columbia Children\u2019s Hospital and University of British Columbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen R.","family":"Nadel","sequence":"additional","affiliation":[{"name":"Department of Radiology, British Columbia Children\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim E.","family":"Potts","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology\/Bone Marrow Transplantation, British Columbia Children\u2019s Hospital and University of British Columbia"},{"name":"Department of Radiology, British Columbia Children\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don C.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Radiology, British Columbia Cancer Agency, University of British Columbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash","family":"Eftekhari","sequence":"additional","affiliation":[{"name":"Department of Radiology, British Columbia Cancer Agency, University of British Columbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca J.","family":"Deyell","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology\/Bone Marrow Transplantation, British Columbia Children\u2019s Hospital and University of British Columbia"},{"name":"British Columbia Children\u2019s Hospital Research Institute, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/asheducation-2013.1.400","article-title":"Management of early-stage Hodgkin lymphoma: is there still a role for radiation?","volume":"2013","author":"Johnson","year":"2013","journal-title":"Am Soc Hematol"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11899-009-0019-0","article-title":"What is the best treatment for children with limited-stage Hodgkin lymphoma?","volume":"4","author":"Keller","year":"2009","journal-title":"Curr Hematol Malig Rep"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1200\/JCO.2014.59.4853","article-title":"Pediatric Hodgkin lymphoma","volume":"33","author":"Mauz-Korholz","year":"2015","journal-title":"J Clin Oncol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.2012.45.3266","article-title":"Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95","volume":"31","author":"Dorffel","year":"2013","journal-title":"J Clin Oncol"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/00043426-200606000-00008","article-title":"POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA1 Hodgkin disease: a report from the Children\u2019s Oncology Group","volume":"28","author":"Kung","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1200\/JCO.2011.41.1819","article-title":"Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin\u2019s lymphoma--a report from the Children\u2019s Oncology Group","volume":"30","author":"Wolden","year":"2012","journal-title":"J Clin Oncol"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1001\/jama.2012.5847","article-title":"Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma","volume":"307","author":"Metzger","year":"2012","journal-title":"JAMA"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.2009.26.9381","article-title":"Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin\u2019s lymphoma: the GPOH-HD-2002 study","volume":"28","author":"Mauz-Korholz","year":"2010","journal-title":"J Clin Oncol"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children\u2019s Oncology Group Study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"J Clin Oncol"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the First International Workshop on interim-PET-scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2013.103218","article-title":"The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale","volume":"99","author":"Gallamini","year":"2014","journal-title":"Haematologica"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers","volume":"54","author":"Biggi","year":"2013","journal-title":"J Nucl Med"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","author":"Hutchings","year":"2006","journal-title":"Blood"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1200\/JCO.2005.04.5823","article-title":"Hodgkin\u2019s lymphoma in adolescents","volume":"24","author":"Foltz","year":"2006","journal-title":"J Clin Oncol"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/annonc\/mdx005","article-title":"ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma","volume":"28","author":"Marr","year":"2017","journal-title":"Ann Oncol"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the Kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochemia Medica"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/JBM.S69267","article-title":"The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin\u2019s disease who achieved complete remission after standard chemotherapy","volume":"6","author":"Bayoumi","year":"2015","journal-title":"J Blood Med"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.ijrobp.2016.07.015","article-title":"Predictive factor analysis of response-adapted radiation therapy for chemotherapy-sensitive pediatric Hodgkin lymphoma: analysis of the Children\u2019s Oncology Group AHOD 0031 Trial","volume":"96","author":"Charpentier","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2008-10-184143","article-title":"A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425","volume":"114","author":"Schwartz","year":"2009","journal-title":"Blood"},{"key":"R27-20230918","first-page":"1","article-title":"Can radiotherapy be omitted in children with Hodgkin lymphoma who achieve metabolic remission on interim positron emission tomography? Experience of a Tertiary Care Cancer Referral Center","volume":"4","author":"Totadri","year":"2018","journal-title":"J Glob Oncol"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2967\/jnumed.109.073197","article-title":"18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma","volume":"51","author":"Cerci","year":"2010","journal-title":"J Nucl Med"},{"key":"R29-20230918","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"R30-20230918","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1182\/blood.V128.22.4156.4156","article-title":"Prognostic value of interim positron emission tomography among children with advanced Hodgkin lymphoma in developing countries: Children Cancer Hospital Egypt experience","volume":"128","author":"Khedr","year":"2016","journal-title":"Blood"},{"key":"R31-20230918","article-title":"Role of 18-FDG-PET\/CT in assessment of pediatric Hodgkin\u2019s lymphoma","author":"El-Saban","year":"2014","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R32-20230918","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2967\/jnumed.116.176511","article-title":"Posttreatment PET\/CT rather than interim PET\/CT using Deauville criteria predicts outcome in pediatric Hodgkin lymphoma: a prospective study comparing PET\/CT with conventional imaging","volume":"58","author":"Bakhshi","year":"2017","journal-title":"J Nucl Med"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:26:44Z","timestamp":1695011204000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001534","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}